Biotheryx
San Diego, US · Founded 2008 · California corporation · 27 employees on LinkedIn · 3 known investors
Biotheryx is a clinical-stage biopharmaceutical company developing first-in-class targeted protein degraders, including molecular glues and bifunctional degraders, with an initial focus on cancer and inflammatory disease. Its drug discovery work is built on modulating Cereblon and its proprietary PRODEGY platform.
Founders & leadership
KC
Kyle Chan, PhDExecutive
LZ
Lawrence ZaslowExecutive
FM
Frank Mercurio, PhDExecutive
LF
Leah FungChief Executive Officer & Board Member (former Chief Scientific Officer)
RW
Raymond W. UrbanskiActing Chief Medical Officer
DS
David Stirling, PhDNamed on SEC filing
PD
Philippe DrouetChief Executive Officer
Board
LD
Louis DeGennaro, PhDBoard director
Investors · 3
Reported raises · per SEC filings
Form D private placements$93.8M disclosed across 4 rounds · 2014–2021
▶$92.1MraisedJun 2021 · 40 investors · BiotechnologyRule 506(b)
▶$92.1MraisedJun 2021 · 40 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Kyle W.H. ChanExecutive Officer
- Dung ThaiExecutive Officer
- Jack NoelkeDirector
- Christopher DevineDirector
- Jaime A. DonadioExecutive Officer
- Louis DeGennaroDirector
- David I. StirlingExecutive Officer, Director
- Frank MercurioExecutive Officer
- Robert F. WilliamsonExecutive Officer, Director
- Offering amount
- $100M
- Amount sold
- $92.1M
- First sale
- May 2021
- Incorporated
- Corporation, California
- Federal exemptions
- 06b
▶$500KraisedMay 2015 · 4 investors · BiotechnologyRule 506(b)
▶$500KraisedMay 2015 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Kyle Chan, PhDExecutive Officer
- David Stirling, PhDExecutive Officer, Director
- Louis DeGennaro, PhDDirector
- Lawrence ZaslowExecutive Officer, Director
- Frank Mercurio, PhDExecutive Officer
- Offering amount
- $6M
- Amount sold
- $500K
- Minimum investment
- $50K
- First sale
- Apr 2015
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$150KraisedSep 2014 · 3 investors · BiotechnologyRule 506(b)
▶$150KraisedSep 2014 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Louis DeGennaro, PhDDirector
- Frank Mercurio, PhDExecutive Officer
- Kyle Chan, PhDExecutive Officer
- Lawrence ZaslowExecutive Officer, Director
- David Stirling, PhDExecutive Officer, Director
- Offering amount
- $6M
- Amount sold
- $150K
- Minimum investment
- $25K
- First sale
- Sep 2014
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1MraisedJun 2014 · 10 investors · BiotechnologyRule 506(b)
▶$1MraisedJun 2014 · 10 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Frank Mercurio, PhDExecutive Officer
- Lawrence ZaslowExecutive Officer, Director
- David Stirling, PhDExecutive Officer, Director
- Louis DeGennaro, PhDDirector
- Kyle Chan, PhDExecutive Officer
- Offering amount
- $5M
- Amount sold
- $1M
- Minimum investment
- $50K
- First sale
- May 2014
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 4
by search overlapBioworld12 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Nurix Therapeutics9 shared keywordsNurix Therapeutics develops targeted protein degradation medicines, including degrader-antibody conjugates (DACs), designed to eliminate disease-causing proteins using the cell's natural degradation machinery. It uses a DEL-AI drug discovery engine to advance a multi-modal clinical pipeline targeting diseases in oncology, immunology, and neurology.
Ultragenyx8 shared keywordsUltragenyx is a biopharmaceutical company that develops and commercializes therapies for rare and ultra-rare genetic diseases. It maintains a broad drug development pipeline focused on rare disease treatments.
Exelixis8 shared keywordsExelixis is an oncology company that discovers and develops cancer treatments, including small molecule therapeutics and biotherapeutics such as antibody-drug conjugates, for patients across multiple tumor types. Its flagship commercial product is CABOMETYX (cabozantinib), and it operates through global development and commercialization partnerships.
Companies competing with Biotheryx for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Biotheryx do?
- Biotheryx is a clinical-stage biopharmaceutical company developing first-in-class targeted protein degraders, including molecular glues and bifunctional degraders, with an initial focus on cancer and inflammatory disease. Its drug discovery work is built on modulating Cereblon and its proprietary PRODEGY platform.
- Who are Biotheryx's investors?
- Biotheryx's investors include Lumira Ventures, Revelation Partners, SR One Capital Management.
- How much funding has Biotheryx raised?
- Biotheryx has disclosed $93.8M raised across 4 rounds.
- Where is Biotheryx headquartered?
- Biotheryx is headquartered in San Diego, US.